Ranjitkar Manandhar, N. et al. 2018. Dasatinib tyrosine kinase inhibitor as second and third line therapy in chronic myeloid leukemia: outcome of a Nepalese study. Journal of Patan Academy of Health Sciences. 5, 1 (Jul. 2018), 47–56.